Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.
Also called NCT03907046
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 700 participants
- Registry
-
NCT03907046
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT03907046. Randomized; quadruple masking; primary purpose prevention. Start 2020-01-28 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Acronym
- ASPIRE
- Condition
- Intracerebral Hemorrhage
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Yale University
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
Record details
- Record id
cardio:ct-nct03907046- Content hash
57f022cb084e11fa8cdc9a8eacdcb34d2d233b795cd12b813f0d12ba95cc6299